Materials exchange deal meager boost to India's biotech

Article Abstract:

An agreement in principle to enable the smooth transfer of microorganisms and biological materials from the US to India is an encouraging sign for Indian bioscience. Discussions between the acting US deputy secretary of commerce David A. Sampson and an Indian delegation in mid-June 2005 led by science minister Kapil Sibal led to the biologics transfer proposal.

Government domestic functions, India, Biotechnology industry, Biotechnology industries, Science and technology policy

---

US food aid still under GM cloud

Article Abstract:

The new policy on Genetically Modified Organism (GMO) imports states that the country exporting GM material should provide comprehensive information and answer all technical queries about biosafety. A controversy whether India should import a shipment of food aid from the US that is suspected to be contaminated with genetically modified (GM) corn is presented.

General services, Imports, Molecular Biological Products, Safety and security measures, Genetically modified organisms, Biotechnology, Genetically engineered foods

---

U.S. biodefense-shocking and awful

Article Abstract:

The Biodefense Advanced Research and Development (BARDA) have to make the U.S. Bioshield Program efficient in terms of clarity in decision making process.

Biological Products, Usage, Vaccines, United States. Biomedical Advanced Research and Development Agency

Similar abstracts:

• Abstracts: The number on biotech indexes. Putting biotech risk in its place. Going short on biotech
• Abstracts: Three US states launch biotech seed funds. Global biotech expansion taking cues from Bayh-Dole. Unlocking the money-making potential of RNAi
• Abstracts: Insect resistance management in GM crops: Past, present and future. Transgenic plants expressing two Bacillus thuringiensis toxins delay insect resistance evolution
• Abstracts: Acquisition signals shift from US market. UK urged to plug "bioprocessing gap"
• Abstracts: Monsanto unaffected by merger halt? California votes for embryonic stem cell research. FDA panel recommends easing gene therapy trial limits

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.